Department of Cardiology, Vivantes Klinikum im Friedrichshain und Am Urban, Berlin, Germany.
Rostock University Medical Center, Rostock, Germany.
Clin Res Cardiol. 2017 Oct;106(10):833-839. doi: 10.1007/s00392-017-1127-9. Epub 2017 Jun 7.
Remote monitoring (RM) of cardiac implantable electronic devices (CIEDs) has been popularized as a precious patients' management tool. We have investigated RM within the premises of a multicenter, prospective, real-world registry, i.e., the German Device II.
We have focused on: (1) CIEDs with RM capabilities implantation rate and (2) actual rate of RM features activation.
A cohort of 1223 CIEDs patients were treated from 04/11 to 02/14. Of these, 720 (58.8%) were implanted with RM-capable devices and were presenting significantly more often a clinical diagnosis of dilatative cardiomyopathy and an indication for cardiac resynchronization. At discharge, the RM feature was activated in only 12.6% (91/720) of the total number of patients implanted with RM-capable CIEDs. After adjusting for implanting center, there was no significant correlation between any of the patient clinical characteristics and RM activation. One-year estimated mortality was 9.0% in patients with activated RM, 5.6% in those with not activated RM, and 7.7% in those without RM capability (p = 0.3). The RM feature was still activated in 13.8% of the patients surviving at follow-up. Patients undergoing RM had a trend for higher re-hospitalization rate and less visits in the device outpatient clinic.
Although RM in CIEDs may be a clinically valuable technological armamentarium, its activation does not reflect patients' clinical profile. In fact, RM is often not activated, most probably because it is still recognized as a source of increased workload in a reality where reimbursement plans for dedicated human resources are not yet optimized.
远程监测(RM)已作为心脏植入电子设备(CIEDs)患者管理的重要工具而得到普及。我们通过多中心前瞻性真实世界注册研究,即德国器械 II 研究,对 RM 进行了调查。
我们主要关注以下两个方面:(1)具有 RM 功能的 CIEDs 的植入率;(2)RM 功能实际激活率。
2011 年 4 月至 2014 年 2 月共纳入 1223 例 CIEDs 患者,其中 720 例(58.8%)植入了具有 RM 功能的设备,且更常患有扩张型心肌病和心脏再同步化治疗的适应证。出院时,仅 12.6%(91/720)的患者激活了 RM 功能。校正植入中心后,RM 激活与患者的任何临床特征均无显著相关性。RM 激活组患者的 1 年死亡率为 9.0%,未激活 RM 组为 5.6%,无 RM 功能组为 7.7%(p=0.3)。随访时存活患者中仍有 13.8%激活了 RM 功能。行 RM 的患者再住院率有增高趋势,在器械门诊就诊次数减少。
尽管 RM 可能是一种有临床价值的技术手段,但它的激活并不能反映患者的临床特征。实际上,RM 功能常未被激活,可能是因为在资源投入尚未优化的现实环境中,RM 功能被认为是增加工作负荷的一个来源。